Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Device approvals, clinical-trial results, and insider trades all live inside AtriCure’s SEC paperwork—but they are hard to spot. Medical-device disclosures run hundreds of pages, packed with FDA language, trial endpoints, and revenue splits between ablation and cryotherapy systems. If you have ever searched for recall language or the latest CryoICE sales trend inside an annual report, you know the challenge.
Stock Titan solves that problem. Our platform delivers AtriCure SEC filings explained simply: AI-powered summaries highlight what changed, why it matters, and where to find detail. Whether you need the AtriCure annual report 10-K simplified for pipeline updates, the AtriCure quarterly earnings report 10-Q filing to compare segment growth, or an AtriCure 8-K material events explained alert on new FDA clearances, we surface it the moment EDGAR publishes. Real-time monitors flag AtriCure Form 4 insider transactions real-time, helping you track AtriCure executive stock transactions Form 4 before markets open. Interactive tables let you drill into cash‐flow swings, R&D spending, and risk-factor revisions—no manual page dives required.
Professionals use these insights to:
- Follow AtriCure insider trading Form 4 transactions ahead of earnings calls
- Compare ablation versus LAA device revenue across quarters with our AtriCure earnings report filing analysis
- Review AtriCure proxy statement executive compensation when evaluating governance
Michael H. Carrel, who serves as President, CEO and a Director of AtriCure, reported a charitable gift of 10,000 shares of AtriCure common stock on 08/08/2025 with no consideration received. After the reported transaction he beneficially owned 697,377 shares directly. The filing also discloses that 9,310 shares are held by his children and 2,250 shares are held by his parents, which he disclaims except for a pecuniary interest. The disclosure is coded as a gift and reflects insider compliance with Section 16 reporting.
AtriCure, Inc. (ATRC) Form 4: Director Regina E. Groves sold 2,452 common shares on 08-06-2025 at a weighted-average price of $36.82, a transaction valued at roughly $90 k.
After the sale, Groves directly owns 33,715 shares. No derivative securities were involved and the filing does not cite a Rule 10b5-1 trading plan. There are no disclosures of additional insider transactions, compensation changes, or company events in this filing.
The reported sale reduced her direct position by about 6.8% (from 36,167 to 33,715 shares). While a single Form 4 offers limited context, investors often track insider activity as a sentiment gauge. This transaction is modest relative to AtriCure’s average daily volume and does not, by itself, indicate a change in corporate fundamentals.
On this Form 4, AtriCure (ATRC) Chief Scientific Officer Vinayak S. Doraiswamy reported an open-market sale of 2,500 common shares on 08/05/2025 at $36.58 per share, yielding roughly $91 K in proceeds. After the transaction, he directly owns 71,872 shares, down about 3.4% from 74,372, leaving a stake worth ~$2.6 M at the sale price. No derivative trades were disclosed, and the filing cites no Rule 10b5-1 plan. Aside from this single sale, the document contains no financial results, guidance, or additional corporate events.
AtriCure, Inc. (ATRC) – Form 144 filing
- Proposed sale: 2,452 common shares (≈0.005% of the 49.7 million shares outstanding).
- Estimated value: US$90,307 based on market price at filing.
- Selling party: Not identified; shares held for the account of an insider who received them as a stock-award (compensation) on 05/20/2021.
- Broker: Fidelity Brokerage Services LLC.
- Planned trade date: on or after 08/06/2025; exchange: NASDAQ.
- No other ATRC shares have been sold by this person in the past three months.
The notice is procedural under Rule 144 and involves a de-minimis volume relative to total float. It has no dilution effect and signals only a routine insider liquidity event. Investors typically view such a small Form 144 filing as neutral and non-material to valuation or governance considerations.
On 30 Jul 2025 AtriCure, Inc. ("ATRC") filed a Form S-8 with the SEC to register 1,700,000 additional shares of common stock for issuance under its 2023 Stock Incentive Plan. Because the company is a large accelerated filer, the shares become eligible for grant immediately upon effectiveness.
The filing incorporates by reference the company’s 2024 Form 10-K, 2025 Form 10-Qs and a recent Form 8-K, and includes standard undertakings and indemnification language. Keating Muething & Klekamp PLL supplied the legal opinion, while Deloitte & Touche LLP provided the auditor’s consent. No new financial statements, pricing terms or selling shareholder information are presented.
The registration expands the equity pool used to attract, retain and motivate employees and directors; however, issuance of the newly registered shares could dilute existing shareholders when awards vest or are exercised.
AtriCure (ATRC) Q2-25 10-Q highlights: Revenue rose 17.1% YoY to $136.1 M, driven by 41% growth in Pain Management and 19% in Appendage Management; Minimally Invasive Ablation fell 34%. International sales advanced 23% (20% cc). Six-month revenue reached $259.8 M, +15.4% YoY.
Gross margin held at 74.5%. Operating loss narrowed to $6.2 M from $7.2 M; net loss improved to $6.2 M (-$0.13 EPS) vs. $8.0 M (-$0.17). YTD net loss nearly halved to $12.9 M. Cash flow from operations swung to +$10.6 M (vs. -$13.6 M). Cash & equivalents ended at $117.8 M; long-term ABL debt unchanged at $61.9 M, leaving $61.9 M in unused capacity.
R&D expense jumped 43% to $29.3 M, including a $5 M milestone for the pulsed-field ablation (PFA) Cooperation Agreement. SG&A rose 6.5% on headcount. Key milestones: FDA 510(k) clearances for AtriClip PRO-Mini and cryoICE cryoXT (launches 2H-25); completion of 6,500-patient LeAAPS stroke-prevention trial enrollment.
Risk factors: a Delaware suit from former SentreHEART holders seeks up to $260 M over PMA milestone; management deems loss not probable/estimable. Minimally invasive revenue weakness and flat margins bear monitoring.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
